Jonathan Tobin

Cincera Therapeutics is a privately held biotechnology company based in Melbourne, Australia. The company is focused on the discovery and development of new drugs aiming to treat difficult-to-treat inflammatory and fibrotic conditions associated with obesity/metabolic diseases, with potential applications in many other disease areas including cancer. The company will initially focus on treatments for the emerging epidemic of a liver disease termed ‘NASH’ (non-alcoholic steatohepatitis). The Cincera team has developed novel drug like lead compounds that specifically inhibit a key enzymatic target in a lipid metabolism pathway. The novel and differentiated approach of Cincera is derived from the innovative research of its academic co-founders: medicinal chemist and entrepreneur Associate Professor Bernard Flynn, from the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University (Monash) in Melbourne, and lipid biologist Professor Stuart Pitson, from the Centre for Cancer Biology (CCB) at the University of South Australia (UniSA) in Adelaide. The company is funded by the Medical Research Commercialisation Fund (MRCF), which is managed by the life science specialist venture capital management firm – Brandon Capital Partners (BCP).

We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

Cincera Therapeutics is a privately held biotechnology company based in Melbourne, Australia. The company is focused on the discovery and development of new drugs aiming to treat difficult-to-treat inflammatory and fibrotic conditions associated with obesity/metabolic diseases, with potential applications in many other disease areas including cancer. The company will initially focus on treatments for the emerging epidemic of a liver disease termed ‘NASH’ (non-alcoholic steatohepatitis). The Cincera team has developed novel drug like lead compounds that specifically inhibit a key enzymatic target in a lipid metabolism pathway. The novel and differentiated approach of Cincera is derived from the innovative research of its academic co-founders: medicinal chemist and entrepreneur Associate Professor Bernard Flynn, from the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University (Monash) in Melbourne, and lipid biologist Professor Stuart Pitson, from the Centre for Cancer Biology (CCB) at the University of South Australia (UniSA) in Adelaide. The company is funded by the Medical Research Commercialisation Fund (MRCF), which is managed by the life science specialist venture capital management firm – Brandon Capital Partners (BCP).

Cancer Research Horizons is Cancer Research UKs innovation engine. We take scientific breakthroughs from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients. To date, we’ve played an instrumental role in forming over 60 spin-out companies and bringing 11 new cancer drugs to market, borne out of our pioneering research. We are the second biggest licensor of cancer research treatments globally and are part of Cancer Research UK – the world’s largest medical research charity. With exclusive rights to over £300m of world-class cancer research we’re a unique and powerful partner in the fight to beat cancer. We work closely with academia and industry to bridge the gap between research and the market, delivering maximum impact for patients. Every penny we make goes back into developing the next breakthroughs, helping bring forward the day when all cancer is conquered.

We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

Brandon Capital is Australasias leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK. Through collaboration and investment, we transform promising medical research breakthroughs into medical therapies that improve patients lives. We have supported more than 50 start-up companies to date, the majority of which were founded by us in collaboration with the inventor and their research institutes. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation. For more information about Brandon Capital, visit www.brandoncapital.vc

Genomics England works with the NHS to bring forward the use of genomic healthcare and research in Britain to help people live longer, healthier lives. Genomics is a ground-breaking area of medicine that uses our unique genetic code to help diagnose, treat and prevent illnesses. Thanks to advanced technology, scientists can now compare many people’s genetic code to make new discoveries that continually improve genomic healthcare. In 2013, Genomics England and the NHS launched the 100,000 Genomes Project, demonstrating how genomics insights can help doctors across the NHS, and building a foundation for the future by assembling a unique dataset. Genomics England is now supporting the NHS to deliver genomic testing for patients as part of routine healthcare, and providing the health data and technology that researchers need to make new discoveries and create more effective, targeted medicines. We work with thousands of people – patients, doctors and scientists – to increase our collective knowledge and enable faster and deeper genomic research, to bring genomic healthcare to all who need it.